Parkinson's Disease/Movement Disorders News

Prothena Corp. recently announced it would receive $80 million from Bristol Myers Squibb for an exclusive global license to an investigational therapeutic developed to address protein dysregulation.

The FDA has granted regenerative medicine advanced therapy designation for an investigational gene therapy to treat Huntington’s disease, according to the manufacturer.

The FDA has approved Austedo XR in four new tablet strengths for adults diagnosed with tardive dyskinesia and chorea associated with Huntington’s disease, according to the manufacturer.

A health care innovation company and a clinical-stage biotech company have announced a partnership to advance a novel apomorphine therapeutic in combination with a wearable drug delivery platform to treat Parkinson’s disease.

Novel forms of a rare genetic variant may contribute to the risk for co-occurring Parkinson’s disease and inflammatory bowel disease, according to research presented in Genome Medicine.

DENVER — Cognitive impairment in Parkinson’s is a mitigating factor for presence of blood-based biomarkers during sleep as indicator of disease progression, according to a poster at the American Academy of Neurology annual meeting.

DENVER — Deterioration of memory and executive functions were associated with worsening quality of life for those with Parkinson’s disease over a 3-year period, according to a poster at the American Academy of Neurology annual meeting.

DENVER — Exposure to airborne manganese may be a significant contributing factor to risk of Parkinson’s disease, according to a poster from the American Academy of Neurology annual meeting.

Nearly all study participants believed to have a synucleinopathy had the presence of alpha-synuclein in their skin samples, according to a study presented at the American Academy of Neurology annual meeting.

DENVER — The American Brain Foundation is funding research to find a cure for Lewy body dementia and discover breakthroughs in neuroinflammation, the group’s executive director said at the American Academy of Neurology annual meeting.